429 related articles for article (PubMed ID: 26162946)
1. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial.
Nishikido T; Oyama J; Keida T; Ohira H; Node K
J Cardiol; 2016 Apr; 67(4):340-6. PubMed ID: 26162946
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
Aydin MU; Aygul N; Altunkeser BB; Unlu A; Taner A
Atherosclerosis; 2015 Apr; 239(2):439-43. PubMed ID: 25697576
[TBL] [Abstract][Full Text] [Related]
3. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
[TBL] [Abstract][Full Text] [Related]
4. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
5. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
[TBL] [Abstract][Full Text] [Related]
7. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
[TBL] [Abstract][Full Text] [Related]
9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
11. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
12. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
13. [Statin therapy for atherogenic hypertriglyceridemia].
Koba S
Nihon Rinsho; 2013 Sep; 71(9):1655-60. PubMed ID: 24205730
[TBL] [Abstract][Full Text] [Related]
14. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
J Atheroscler Thromb; 2011; 18(11):1018-28. PubMed ID: 21921413
[TBL] [Abstract][Full Text] [Related]
15. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.
Welty FK; Lewis SJ; Friday KE; Cain VA; Anzalone DA
J Womens Health (Larchmt); 2016 Jan; 25(1):50-6. PubMed ID: 26539650
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
[TBL] [Abstract][Full Text] [Related]
19. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
20. Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
